
Mix of porcine brain-derived neuropeptides — neuroprotector approved in 50+ countries for Alzheimer's, stroke, and dementia.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Cerebrolysin is not a single peptide but a standardized mixture of low-molecular-weight peptides (under 10 kDa) and free amino acids obtained by controlled enzymatic digestion of porcine brain proteins. Ever Pharma (Austria) has produced it since the 1950s, and it is a biological product: its composition is defined by the manufacturing process rather than a chemical formula, so it has no single sequence or molecular mass. Renova's vial contains 60 mg of the lyophilized peptide fraction.
The working hypothesis is that the mixture mimics endogenous neurotrophic factors such as BDNF, NGF and CNTF: in neuronal cultures and in animal models of ischemia, trauma and neurodegeneration it reduces apoptosis, modulates calpain and GSK-3β signaling, favors neurogenesis and synaptogenesis and attenuates the inflammatory response. Being a mixture, attributing each effect to a specific component is difficult, which complicates its pharmacological characterization.
It is authorized in some fifty countries — Russia, China, Austria, South Korea, much of Eastern Europe and Latin America — for stroke, traumatic brain injury and dementias, always by the intravenous or intramuscular route; the product label specifies it must not be given subcutaneously. Cochrane reviews on acute stroke and vascular dementia judge the evidence of benefit uncertain or low-quality. It holds no FDA approval and no centralized EMA approval. Renova distributes it for research only.
| Class | Porcine-derived neurotrophic peptide mixture (biological product) |
| Composition | Peptides < 10 kDa (≈ 25%) and free amino acids (≈ 75%) from porcine brain; no single sequence |
| Reference producer | Ever Pharma (Austria), since the 1950s |
| Proposed mechanisms | BDNF/NGF/CNTF mimicry; ↓ apoptosis (calpain, GSK-3β); neurogenesis; anti-inflammatory |
| Clinical routes | Intravenous or intramuscular; the product label excludes the subcutaneous route |
| Regulatory status | Authorized in ≈ 50 countries; no FDA approval; Cochrane reviews: uncertain evidence |
| Note | Animal origin: lot-to-lot variability and biological-product considerations |
| Renova presentation | 60 mg lyophilized fraction; research only |
Not exactly: it is a mixture of many small peptides and amino acids obtained from pig brain proteins. That is why it has no single sequence or molecular weight, and its identity is defined by the manufacturing process. In that sense it resembles a standardized extract more than a synthetic compound.
In around fifty: Russia, China, Austria, South Korea and much of Eastern Europe and Latin America, for stroke, head trauma and dementias, by the intravenous or intramuscular route. It has no FDA approval. Renova's product is research material, not the registered medicine.
Cochrane reviews on acute ischemic stroke and vascular dementia conclude that the evidence of benefit is uncertain or low-quality, with heterogeneity between trials and risk of bias. Meta-analyses by authors linked to Ever Pharma are more favorable. It is a case where the breadth of clinical use exceeds the strength of the evidence.
Because all clinical experience and safety studies correspond to the intravenous and intramuscular routes, and the product label expressly excludes the subcutaneous one. In research that restriction is a relevant input for experimental design.
Related reading: Cerebrolysin: Neurotrophic Peptide Blend · Semax and Selank: The Russian Peptide Nootropics
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty